Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab Combination Presented at the 2026 European ...
- frontMIND study evaluating tafasitamab (Monjuvi ® /Minjuvi ® ) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA …